Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Status:
Terminated
Trial end date:
2016-12-19
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the incidence of human anti-chimeric antibody (HACA)
in high-risk neuroblastoma patients treated with Unituxin combination therapy.